TRANSFAC FACTOR TABLE, Release 2017.2 - public - 2017-06-30, (C) QIAGEN

AC T05450 XX ID T05450 XX DT 24.02.2003 (created); oke. DT 01.04.2009 (updated); pum. CO Copyright (C), QIAGEN. XX FA C2TA XX SY C2TA; Class II TransActivator. XX OS human, Homo sapiens OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; primates XX GE G002341 CIITA; HGNC: CIITA. XX SF non DNA binding transactivator; SF ah1 and ah2 are of particular importance for the activation of DRA promoter and for full interaction with general transcription factor TAFII32, C2TA with deletion of ah12 represents a dominant negative factor [5]; SF P/S/T domain is essential for the transactivation by C2TA [6]; SF GTP-binding motifs are similar to those of GTP-binding molecules in the Ras superfamily [6]; SF acidic activation domain is essential for the interactions with the components of the basal transcriptional machinery [5] [7]; SF C-terminal part of the protein is involved in the interactions with RFX5 [8]; SF LRR region is essential for function, it provides nuclear localization of C2TA and in vivo recruitment to the MHC class II promoters [10]; XX CP B-cell [11]. XX FF transcriptional coactivator via interactions with DNA-binding proteins that bind to these promoters [11]; FF strong co-activator of transcription initiation; FF belongs to the class of acidic activators, like VP16, CTF/NF-1; FF master regulator of MHC class II gene expression; FF gene is mutated in MHC class II deficiency (complementation group A) [1]; FF due to the direct interactions with RFX5 serves as a molecular bridge between the RFX complex and basal machinery [2] [8]; FF interacts directly with TAFII32 T02113 [5] [7]; FF interacts directly with TAFII70 T00783 [7]; FF interacts directly with TFIIB T00818 [7]; FF interacts directly with RFX5 subunit of the RFX complex [2] [10]; FF interacts directly with RFXANK subunit of the RFX complex [10]; FF interacts directly with NF-YB and NF-YC subunits of the NF-Y complex [10]; FF is able to stimulate elongation of transcription, like VP16 [7]; FF cooperates with CREB ( X2-box binding protein) to activate MHC class II transcription [4]; FF induces promoter occupation by higher-order RFX-X2BP-NFY complexes, likely in a cell type-specific manner [9]; XX IN T00154 NF-YB; human, Homo sapiens. IN T02478 NF-YC-isoform3; human, Homo sapiens. IN T05351 PPARgamma; human, Homo sapiens. IN T01672 rfx5; human, Homo sapiens. IN T05441 RFXANK; human, Homo sapiens. IN T02113 TAFII31; human, Homo sapiens. IN T00783 TAFII70-alpha; human, Homo sapiens. IN T00818 TFIIB; human, Homo sapiens. XX BS R18813. XX DR TRANSPATH: MO000034869. DR UniProtKB: P33076; XX RN [1]; RE0008252. RX PUBMED: 8402893. RA Steimle V., Otten L. A., Zufferey M., Match B. RT Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome) RL Cell 75:135-146 (1993). RN [2]; RE0022539. RX PUBMED: 10938133. RA DeSandro A. M., Nagarajan U. M., Boss J. M. RT Associations and interactions between bare lymphocyte syndrome factors. RL Mol. Cell. Biol. 20:6587-6599 (2000). RN [3]; RE0022540. RX PUBMED: 9722631. RA Brown J. A., Rogers E. M., Boss J. M. RT The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element. RL Nucleic Acids Res. 26:4128-4136 (1998). RN [4]; RE0022543. RX PUBMED: 10072067. RA Moreno C. S., Beresford G. W., Louis-Plence P., Morris A. C., Boss J. M. RT CREB regulates MHC class II expression in a CIITA-dependent manner. RL Immunity 10:143-151 (1999). RN [5]; RE0022565. RX PUBMED: 9171108. RA Fontes J. D., Jiang B., Peterlin B. M. RT The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32. RL Nucleic Acids Res. 25:2522-2528 (1997). RN [6]; RE0022567. RX PUBMED: 9122224. RA Chin K. C., Li G. G., Ting J. P-Y. RT Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: generation of transdominant-negative mutants. RL Proc. Natl. Acad. Sci. USA 94:2501-2506 (1997). RN [7]; RE0022568. RX PUBMED: 9177216. RA Mahanta S. K., Scholl T., Yang F. C., Strominger J. L. RT Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. RL Proc. Natl. Acad. Sci. USA 94:6324-6329 (1997). RN [8]; RE0022569. RX PUBMED: 9177217. RA Scholl T., Mahanta S. K., Strominger J. L. RT Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5. RL Proc. Natl. Acad. Sci. USA 94:6330-6334 (1997). RN [9]; RE0022576. RX PUBMED: 10221658. RA Villard J., Muhlethaler-Mottet A., Bontron S., Mach B., Reith W. RT CIITA-induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter-bound multi-protein complexes. RL Int. Immunol. 11:461-469 (1999). RN [10]; RE0022578. RX PUBMED: 11003667. RA Hake S. B., Masternak K., Kammerbauer C., Janzen C., Reith W., Steimle V. RT CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation. RL Mol. Cell. Biol. 20:7716-7725 (2000). RN [11]; RE0035361. RX PUBMED: 11101876. RA Piskurich J. F., Lin K. I., Lin Y., Wang Y., Ting J. P., Calame K. RT BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. RL Nat. Immunol. 1:526-532 (2000). RN [12]; RE0047255. RX PUBMED: 14678199. RA Rousseau P., Masternak K., Krawczyk M., Reith W., Dausset J., Carosella E. D., Moreau P. RT In vivo, RFX5 binds differently to the human leucocyte antigen-E, -F, and -G gene promoters and participates in HLA class I protein expression in a cell type-dependent manner RL Immunology 111:53-65 (2004). RN [13]; RE0050639. RX PUBMED: 17611194. RA Yong X., Farmer S. R., Smith B. D. RT PPARgamma interacts with CIITA/RFX5 complex to repress collagen type I gene expression. RL J. Biol. Chem. 282:26046-26056 (2007). XX //